5th Edition of International Heart Congress
June 24-26, 2027 | Hybrid Event
Vein Graft Disease
Vein graft disease is a condition that often arises after coronary artery bypass surgery, where a vein from the patient's leg is used to create a bypass around a blocked coronary artery. Over time, these grafts can undergo pathological changes, leading to the development of vein graft disease. The process involves a series of complex events, including inflammation, oxidative stress, and the formation of atherosclerotic plaques within the graft. As vein graft disease progresses, it can compromise blood flow to the heart, ultimately impacting the success of the bypass procedure. Researchers and clinicians focus on understanding the molecular and cellular mechanisms underlying vein graft disease to develop strategies for prevention and intervention, aiming to improve the long-term outcomes of coronary artery bypass grafting procedures.
Agustin Joison
Cordoba Catholic University, Argentina
Thomas J Webster
Brown University, United States
Federico Benetti
Benetti Foundation, Argentina
Thomas J Webster
Brown University, United States
Federico Benetti
Benetti Foundation, Argentina
Mekhman N Mamedov
National Research Center for Preventive Medicine, Russian Federation
Syed Raza
Awali Hospital, BahrainSubmit your abstract Today
Title : Healing a broken heart: One nano beat at a time
Thomas J Webster, Brown University, United States
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Antidiabetic agents – From treating diabetes to providing positive cardiovascular outcome
Syed Raza, Awali Hospital, Bahrain